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Pembasmian sel kanser yang tidak menyeluruh berdasarkan rawatan tunggal 
kemoterapi atau terapi radiasi seringkali dilaporkan. Justeru, peranti nano berasaskan 
nanokulit emas mula diminati kerana kebolehubahan teras dan lapisan biofungsi juga 
resonans plasmon permukaan tempatan (LSPR) daripada gelombang cahaya nampak ke 
inframerah (NIR) yang sesuai untuk aplikasi biomedikal. Dalam projek ini, nanokulit 
emas (GNS), yang berteraskan nanopartikel silika mesoliang (MSN) berisi doxorubicin 
(DOX) serta polietilina glikol (PEG) dan AS1141 aptamer (Apt) pada lapisan luar (DOX-
GNS-PEG-Apt), telah direka untuk terapi pengaktifan kimia dan fototerma menggunakan 
laser dua foton. Teras MSN disintesis melalui proses Stöber diikuti dengan pengisian 
DOX dan akhirnya tumbesaran lapisan emas pada permukaan MSN melalui proses 
pengantara pertumbuhan. Seterusnya, PEG dan Apt dikonjugat pada GNS. GNS yang 
disintesiskan dan pengubahsuaian permukaannya telah dicirikan menggunakan 
Transformasian Fourier Inframerah (FTIR), spektroskopi Ultraungu-Nampak (UV-Vis) 
dan Mikroskop Penghantaran Elektron (TEM). Keputusan menunjukkan 30.00  2.91 % 
doxorubisin (DOX) telah dimuatkan ke dalam MSN. GNS yang disintesis kemudiannya 
dianalisa menggunakan UV-Vis dan TEM, dimana nisbah 4:1 K-emas kepada bijian 
MSN-NH2 menghasilkan ketebalan emas yang sesuai. Nanopartikel dengan liputan emas 
lengkap pada teras silika mesoliang diperhatikan dan spektra penyerapan plasmon 
memuncak pada 800 nm. Berdasarkan data TEM dan Tenaga Penyebaran Sinar X (EDX), 
xvi 
filem emas yang disintesis melalui proses pengantara pertumbuhan adalah sekitar 10 - 15 
nm tebalnya. Kemudian, eksitasi dua foton (TPE) diperkenalkan untuk menilai 
keberkesanan terapi phototerma (PTT) sahaja dan terapi sinergi kimia dan fototerma. 
Kecacatan GNS berlaku selepas pendedahan selama 10 saat kepada TPE pada gelombang 
850 nm, lalu membolehkan pelepasan dadah kemoterapi terkawal dari rongga mesoliang. 
Kecacatan GNS dibuktikan dengan penganjakan puncak resonans plasmon dari 800 ke 
570 nm dan morfologi bagi GNS selepas TPE disahkan lagi dengan TEM. Menurut kajian 
in vitro, DOX-GNS-PEG-AS1141 melekat secara selektif pada sel MDA-MB-231 (kanser) 
tetapi tidak pada sel MCF-10A (bukan kanser), kerana sel-sel kanser mempamerkan 
banyak reseptor nukleolin yang boleh melekat pada AS1141. Penggunaan DOX-GNS-
PEG-AS1141 sahaja tanpa PTT juga tidak sitotoksik; kefahaman sel MDA-MB-231 
apabila dirawat sehingga 100 μg/mL DOX-GNS-PEG-AS1141 tidak jauh berbeza dengan 
kawalan negatif. Sebaliknya, sel MDA-MB-231 yang dikenakan terapi sinergi kimia-
fototerma terapi bersama DOX-GNS-PEG-Apt selepas TPE mempamerkan intensiti 
pendarfluor YO-PRO yang lebih tinggi, 8.38 ± 2.11 kali ganda apabila terdedah kepada 
TPE pada 850 nm dengan kuasa output 55 mW/μm2, berbanding rawatan PTT sahaja 
dengan GNS-PEG-Apt yang memaparkan kenaikan 6.89 ± 2.05 kali. Hasil ini 
menunjukkan terapi sinergi kimia-fototerma merupakan terapi yang berkesan. 
Kesimpulannya, GNS adalah nanoplatform yang boleh menjanjikan gabungan teknik 






MULTIFUNCTIONAL GOLD-SILICA COMPOSITE PLATFORM TOWARDS 
COMPREHENSIVE CANCER THERAPY 
ABSTRACT 
Incomplete cancer cells eradication with sole treatment of chemotherapy or 
radiation therapy was commonly reported. Therefore, gold nanoshells-based nanodevices 
have gained interests owing to the tuneablity of the localised surface plasmon resonance 
(LSPR) from visible to near infrared (NIR) wavelength, which is favourable for 
biomedical applications. In this work, gold nanoshell (GNS), of which has mesoporous 
silica nanoparticle core (MSN) filled doxorubicin (DOX) as well as polyethylene glycol 
(PEG) and AS1141 aptamer (Apt) at the outer layer (DOX-GNS-PEG-Apt), was designed 
for two photon laser-triggered chemo- and photothermal therapy. The results show 30.00 
 2.91 % of doxorubicin (DOX) was loaded into MSNs. The synthesised GNS was then
analysed by UV-Vis spectroscopy and TEM, of which 4:1 ratio of K-gold to MSN-NH2 
seed produced ideal gold thickness. The nanoparticles with a complete gold coverage on 
mesoporous silica core were observed.  Based on the TEM and Energy Dispersive X-Ray 
spectroscopy (EDX) data, the gold film synthesised via grow-mediated process was 
approximately 10 – 15 nm thickness. Then, two photon excitation (TPE) was introduced 
to evaluate the efficacy of photothermal therapy (PTT) alone and the synergistic chemo-
photothermal therapy. Deformation of GNS was evidenced by the blue shift of plasmon 
resonance peak from 800 to 570 nm and the morphology of the GNS after TPE was further 
confirmed with TEM. According to the in vitro study, DOX-GNS-PEG-Apt positive 
selectively bound to MDA-MB-231 cells (cancerous) but not MCF-10A cells (non-
cancerous). In this work, synergistic chemo-photothermal therapy with DOX-GNS-PEG-
xviii 
Apt treated MDA-MB-231 cells after TPE exhibited higher YO-PRO-1 fluorescence 
intensity，8.38 ± 2.11 folds with output power at 55 mW/µm2, as compared to PTT alone 
with GNS-PEG-Apt which only exhibited 6.89 ± 2.05 fold increment. This result 
demonstrated synergistic chemo-photothermal therapy exhibited a better therapy. Taken 
together, GNS is a promising nanoplatform for dual controlled drug release and 







Nanotechnology opens a new avenue towards successful cancer diagnosis and treatment, 
and astounding results in clinical trials have been reported. There are several 
comprehensive reviews available on the challenges and opportunities of nanotechnology 
for cancer therapy (Friberg and Nystrom, 2015, Wicki et al., 2015, Kobayashi and Lin, 
2006, Kawasaki and Player, 2005). It is recognised that nanotechnology exhibits the 
potential in replacing current cancer treatments due to the ability for specific targeting 
(Climent et al., 2012, Li et al., 2012a). Antibody or short peptide conjugated on drug-
loaded nanoparticles selectively target specific cell surface receptor on cancer cells; 
ultimately, sufficient dosage of chemotherapeutic drug is delivered to cancer cells while 
limiting toxicity in healthy cells. Thus, a high dosage of drug is not required to exert the 
same or even better efficacy, which ultimately reduces the cost of treatment. Also, the 
ability of chemotherapeutic drug to be controlled released by external (light, magnetic 
field and ultrasound) (Rodzinski et al., 2016, Ge et al., 2012, Angelatos et al., 2005) or 
internal (pH, temperature) (Lee et al., 2010, Liu et al., 2010, Angelos et al., 2009, Du et 
al., 2009, Zhang and Misra, 2007, Huang et al., 2004) stimuli reduces the chances of 
premature drug release during its transport. Application of nanotechnology in curing 
cancer cells has other advantages over conventional cancer therapy including prolonged 
circulation time and enhanced solubility of chemotherapeutic drugs. 
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Several types of nanosystems including metallic nanoparticle (Baffou and Quidant, 2013, 
Ahmad et al., 2010, Kogan et al., 2007), polymer nanoparticle (Du et al., 2011, Tang et 
al., 2009, Mukerjee and Vishwanatha, 2009, Tong and Cheng, 2007), silica nanoparticle 
(Argyo et al., 2014, Zhang et al., 2012, Lee et al., 2011, Yu et al., 2011, Liu et al., 2009), 
quantum dot (Delehanty et al., 2009, Medintz et al., 2005, Michalet et al., 2005), liposome 
(Allen and Cullis, 2013, Chang and Yeh, 2012, Harris et al., 2002, Batist et al., 2001), 
dendrimer (Wolinsky and Grinstaff, 2008, Tomalia et al., 2007, Majoros et al., 2006, 
Majoros et al., 2005, Malik et al., 1999) and carbon nanotube (Kostarelos et al., 2009, Liu 
et al., 2008, Kam et al., 2005) were developed. Among the mentioned nanosystems, gold 
nanoparticles (AuNP) have drawn wide attention from numerous researchers due to their 
inherent attributes such as chemical stability and excellent optical properties. Also, AuNP 
has high photothermal efficiency thanks to localised surface plasmon resonance (LSPR) 
that make AuNP nanostructures as an attractive platform for biomedical applications (Jain 
et al., 2006, Link and El-Sayed, 2000, Elghanian et al., 1997). Au possesses an excellent 
oxidation resistance which does not interfere with its usability under atmospheric 
conditions thus making it an outstanding candidate for both in vitro and in vivo 
applications. Owing to the strong affinity of the gold-sulfur (Au-S) bond and physical 
absorption, Au offers ease of conjugation to various biological molecules (antibodies, 
DNA and peptide) that have been widely used in sensing, molecular imaging and drug 
targeting (Xie et al., 2010).   
 
Instead of the classic AuNP, many other forms of Au nanostructures have been reported 
such as nanorods (Cabada et al., 2012, Murphy et al., 2005), nanospheres (Daniel and 
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Astruc, 2004), nanoshells, nanoplate nanocages (Hu et al., 2006) and nanoframes. A great 
effort nowadays is done on gold nanoshells (GNS) as they offer tuneable LSPR from 
visible to near infrared (NIR) wavelength by adjusting the core-to-shell ratio. NIR, also 
referred to as “biological window”, allows deep penetration into soft tissues as the 
absorption of light in blood and water is limited and the magnitude of scattering in tissues 
is relatively low. In 2003, localised temperature increment to 37.4 ± 6.6°C with metal 
nanoshell silica core was first reported by Halas group and showed interesting positive 
results (Hirsch et al., 2003). Photothermal conversion upon laser irradiation contributes to 
the localised hyperthermia that causes irreversible cell death. This process is confined to 
nanoparticles distributed area via three potential mechanisms: damage to the cell 
membrane, prompt protein denaturation and induce production of reactive oxygen species 
(ROS). Exploration on metal nanoshell against cancer cells has been done by numerous 
researchers as this approach offers very little complications to the surrounding cells and 
fast recovery to the damaged site.   
 
Lately, multifunctional nanosystems that provide the combination of both chemo- and 
photothermal therapy with metal nanoshell were reported. Wu and colleagues designed a 
system conveying both chemo- and photothermal therapy using gold nanoshell silica core 
with liposome; the synergistic system had better as anticancer efficacy as compared to 
either treatment alone (Wu et al., 2011). Laser irradiation induces localised hyperthermia 
and simultaneously deforms the gold nanoshell. In turn, chemotherapeutic drug is released 
gradually, in controlled-release manner, into the cancer cells thus causing cell death. 
However, the said system by Wu and colleagues is not suitable for in vivo studies as there 
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was absence of target scheme such as antibodies or peptides. Instead of liposome, polymer 
nanoparticles with poly (lactic acid) and poly (lactic-co-glycolide) (Hao et al., 2015, Yang 
et al., 2009), which was synthesised as a core and template for chemotherapeutic drugs 
loading. Another multimodal treatment for cancer was done by Liu et al. with Au-coated 
silica nanorattles loaded with docetaxel (DTX), the treatment successfully induced a 
localised hyperthermia and delivered the drug into human liver carcinoma (HepG2) cells 
(Liu et al., 2011).  
 
To date, there was no known investigation on mesoporous silica nanoparticles (MSNs) 
coated with a thin layer of gold. MSNs have been suggested as a suitable platform for 
biomedical applications as they are biocompatible and biodegradable. Significant efforts 
have been dedicated to the development of MSNs as they offer numerous advantages such 
as a large surface area and ordered mesoporous channels, allowing higher payload of 
fluorescent dye, peptide and drug. Also, the well-defined surface chemistry of MSNs 
allows direct functionalisation and thus targeting specific site and prolonging the 
circulation time in the body (Figure 1.1). A major advantage of MSNs is they hold a 
sustained slow drug release property (Owens et al., 2016, Tang et al., 2014) and the rate 
of drug release can be tuned unlike liposome and polymer nanoparticles, which exhibit a 
burst release of drug. 
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Figure 1.1: Multifunctional and cargo loading of mesoporous silica nanoparticles (MSNs). 
Adapted from Oupicky, 2014. 
 
Many efforts have been made in designing nanodevices in recent years, however, most of 
the designed nanodevices offer only single cancer treatment that may lead to the 
incomplete eradication of cancer cells (Abbasian et al., 2017). Furthermore, traditional 
UV light-responsive nanodevices have been widely reported in literature but these 
nanodevices are not recommended for in vitro and in vivo applications. This owes to the 
UV light property that can cause the detrimental photochemical reactions and also has 
very limited tissue penetration depth (Olejniczak et al., 2015). 
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Herein, mesoporous silica nanoparticles (MSNs) coated with a layer of gold shell were 
synthesised for their multifunctionality including specific targeting, chemo- and 
photothermal therapy. Deformation of gold nanoshell upon two photon excitation (TPE) 
lead to localised temperature increment via photothermal conversion. At the same time, it 
allows the controlled release of the anticancer drug from the mesoporous silica core. 
Combination of both chemotherapy and photothermal therapy via multimodal 
nanoparticles promise a more comprehensive cancer treatment with minimal side effects 
on healthy cells.  
 
1.1 Objectives of the study  
1.1.1 General objectives  
1. To synthesise, functionalise and characterise MSNs coated with a layer of gold shell 
(GNS).  
2. To demonstrate two photon laser triggered gold nanoshell deformation via UV-VIS 
spectroscopy and TEM.  
3. To evaluate the photothermal conversion efficacy of gold nanoshell.  
4. To determine cytotoxicity of gold nanoshell in in vitro studies. 
 
7 
1.1.2 Specific objectives 
1. MSNs, as a template for drug loading will be synthesised via Stöber process and it 
will then be covered by a layer of gold nanoshell by seed-mediated method to avoid 
premature release. 
2. GNS surface will be functionalised with polyethylene glycol (PEG) followed by 
aptamer conjugation. The specificity of aptamer will be evaluated with two cell types. 
3. GNS in aqueous solution will be excited with two photon laser and the final products 
will be collected and characterised.  
4. Different concentration of GNS solution will be prepared and irradiated with 800 nm 
continuous wave (CW) laser as a proof-of-concept for 15 mins. 
5. The toxicity of the DOX-GNS-PEG-Apt will be evaluated via cell meterTM 
colorimetric cell cytotoxicity assay kit. 
6. In vitro cytotoxicity effect of two photon excitation (TPE) induced gold nanoshell 







In this chapter, properties of gold nanoshell (GNS) followed by a brief introduction of the 
inner core, mesoporous silica nanoparticles (MSNs) will be introduced. The reasons 
behind MSNs gaining popularity for drug delivery will be discussed. Next, the target 
scheme on the GNS will be focused on aptamer. In addition, overview of doxorubicin 
(DOX) as well as the anti-tumour strategy will be described. Finally, the basic principle 
of two photon excitation (TPE) and its applications, such as controlled release and induced 
photothermal therapy (PTT), will also be reviewed. 
 
Nanotechnology has made significant contributions to cancer therapy over the past several 
decades. Several nanoparticles such as Doxil, DaunoXome, Marqibo and Abraxaxane 
have been approved by Food and Drug Administration (FDA) for cancer treatment 
however, these nanoparticles are non-targeted delivery nanosystem which may eventually 
cause off target toxic effects (Smith, 2013). Thus, a tremendous efforts have been devoted 
to develop targeted drug delivery nanosystem and a number of these nanosystems for 
instance MM-302, BIND-014 and MBP-426 have been developed and are now in clinical 
trials (2016, 2014, Hrkach et al., 2012). Although these targeted nanomedicines appear to 
be very promising, these systems have the potential to cause the incomplete eradication 
of cancer cells as the designed nanomedicines offer only single cancer treatment, which 
is chemotherapy (Abbasian et al., 2017). Novel nanoparticles with targeting property and 
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synergistic therapeutic effects are demanded for more intensive and effective cancer 
therapy and hence, targeted GNS with synergistic chemo-photothermal therapy was 
designed in this work. 
 
2.1 Gold nanoshells (GNS) 
To date, there is a surge of interest in using a single sophisticated nanodevice for both 
diagnostic and therapeutic purposes. Spherical gold nanoparticles (AuNP) with excellent 
biocompatibility and optical properties had been incredibly conceived as the ideal contrast 
agents for oncological imaging and delivery vehicle for centuries. However, a major 
drawback of the conventional AuNP is its inability to shift the surface plasmon resonance 
(SPR) over a broad wavelength, thus limiting the uses of AuNP in medical applications. 
SPR is a physical process occurs when incident light at a specific angle, called resonance 
angle, hits the metallic surface causing the generation of optical properties. At present, 
different shapes of gold nanostructure such as cube, rod, disk and shell have been designed 
to overcome the shortness of spherical AuNP, which is the inability to shift the SPR over 
a broad wavelength. In recent years, there is a growing interest in using gold nanoshells 
(GNS) for targeted cancer therapies (Zhao et al., 2014). GNS was first invented by Halas 
group consisting a dielectric core surrounded by a controlled thickness of gold layer 
(Averitt et al., 1997). Gold-coated dielectric core particles are biocompatible and have 
outstanding molecular properties. Likewise, the SPR band generated can be easily tuned 
from visible to near infrared (NIR) wavelength through adjustments of the core/shell size 
ratio.  
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The tunable SPR of GNS over a wide region spectrum was first theoretically calculated 
and proposed by Neeves and Birnboim in 1989 (Neeves and Birnboim, 1988). Based on 
the calculation, a red shift of the spectrum would be expected as the shell thinned (Figure 
2.1). This theory was then proved by Oldenburg et al. as 120 nm silica cores were prepared 
to generate GNS with shell thickness ranging from 20 to 33 nm ± 4 nm (Oldenburg et al., 
1998). The ability to tune SPR of GNS from 520 nm to 800 nm (NIR region) where the 
biological tissues transparent window is located, offers tremendous opportunity in medical 
fields, including bio-imaging, biomolecular sensing and cancer therapy (Zhao et al., 2014). 
The ability of GNS to convert absorbed light into heat can kill cancer cells while addition 
of target scheme on the GNS promise nearby healthy tissues unharmed. Likewise, GNS 
is gaining popularity as it displays higher two photon induced photoluminescence (TPIP) 
which is appropriate for three dimensional in vivo fluorescence bio-imaging (Gao et al., 
2011). This statement was supported by Park et al., who found that a red shift of the 
spectrum would be expected as the shell thinned at brightness by TPIP of GNS is 140 
times than fluorescent beads but slightly lower than gold nanorod (GNR) under the same 
condition (Park et al., 2008). Overall, GNS has opened up a new frontier in medical 
research especially in bio-imaging and drug delivery application.  
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Figure 2.1: Theoretically calculated optical resonance of GNS over a range of core 
radius/shell thickness ratio. Adapted from Kim and Lee, 2015 and Loo et al., 2004.  
  
GNS comprising a silica dielectric core have been extensively researched owing to both 
materials that are bioinert materials (Fay et al., 2015, Bear et al., 2013). Moreover, silica 
nanoparticle is preferred for use as this material is inexpensive, environmentally friendly, 
and easy to synthesise and functionalise. However, in this study, mesoporous silica 
nanoparticles (MSNs) will be facilitated as inner core instead of solid silica nanoparticles, 
which is more suitable for drug loading. In particular, MSNs-based drug carriers have 




2.2 Mesoporous silica nanoparticles (MSNs) as drug carriers 
MSNs have gained substantial attention over the past few years. The synthesis, 
advantageous structural properties and recent progress in biomedical applications have 
been extensively discussed in literature, and is summarised in this subtopic.  
 
Unlike solid silica nanoparticles, MSNs are porous material hence making MSNs suitable 
for further physical and biochemical modifications MSNs were first generated in 1992 by 
Kresge and co-workers. At that time, MSNs were known as mobile crystalline material-
41 (MCM-41), which composed of a highly ordered pore arrangement and pore size 
ranging from 2 to 10 nm (Kresge et al., 1992). The invention of MSNs has overcome the 
shortcoming of the traditional formation of zeolite – the first known primitive porous 
material, which term coined in 1756 (Taboada et al., 2005). MSNs have been favourite 
raw materials in industry for several reasons: (1) large surface area whereby, > 700 m2g-1 
permits various modifications to be done (2) large pore volume enables high drug loading 
capacity for up to 200 - 300 mg in 1 g of silica (Bharti et al., 2015) (3) good 
biocompatibility (4) high chemical and thermal stability (5) low cytotoxicity (6) ease of 
functionalisation and (7) delivering variety of drugs in a controllable and sustainable 
manner. All these features make MSNs highly attractive for use in diverse biomedical 
applications: bioimaging, biosensing and drug delivery. MCM-41 introduced by Kresg et 
al. is not suitable for medical application due to the size of particle is too big and 
aggregation issue, which eventually hinder cellular uptake efficiency and causes vascular 
embolisation (Faraji and Wipf, 2009). Also, at cellular level, uptake of nanoparticle is size 
dependent with an optimum particle size of 100 nm is ideal for endocytosis (Xu et al., 
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2012). For these reasons, enormous efforts have been devoted to utilise MSNs over solid 
silica nanoparticles and to synthesise MSNs in the nanometer range that is suitable for 
multimodal drug delivery.  
 
In 2001, MSNs were employed as drug carrier by Vallet-Regi and coworkers for the first 
time (Vallet-Regi et al., 2001). In a particular study, ibuprofen which is a hydrophobic 
drug was loaded into the mesopores of MCM-41 with drug loading ratio of 30 % - by 
weight. It was also observed that 80 % of the loaded drug was released in a substantial 
manner within three days. Since then, delivering drug via MSNs has gained interests as 
reflected by an increase of research papers published while reporting MSNs as drug 
carriers. Another distinctive feature in supporting MSNs as drug carriers is the ability of 
MSNs to entrap both hydrophobic and hydrophilic drugs within their pores. Thus, the 
MSNs scaffold protect the encapsulated therapeutic drugs from direct enzymatic 
degradation in the process of drug delivery (Li et al., 2012b). At the same time, 
characteristics of on demand and time-controlled drug release are highly desirable. Hence, 
an MSN-based stimuli responsive system for controlling spatiotemporal release of drugs 
was designed to only exert an action at the desired target and time. In 2003, Lai and 
colleagues first proposed stimuli (chemical) responsive MSNs in which the opening pores 
were capped with cadmium sulfide (CdS) nanocrystals (Lai et al., 2003). The rapid release 
of drugs was observed only when the MSNs were exposed to thiol reducing agents 
(mercaptoethanol and dithiothreitol), both of which offset other pitfalls in the system and 
still cleaved the disulfide bond efficiently between MSNs and CdS (Figure 2.2). Likewise, 
zero premature release of drugs was recorded, thus the interaction between drugs and 
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normal healthy tissues during its circulation was minimised. This delivery system is 
particularly useful in delivering genotoxic drugs like chemotherapeutic drugs. Several 
stimuli other than chemical such as light, temperature and ultrasound, were also used to 
trigger drug release in a controlled manner. In this study, drug-loaded MSNs were covered 
by a layer of ultra-thin gold forming shell to avoid the premature release of drugs. 
Deformation of GNS occurred upon two photon excitation and subsequently release the 






Figure 2.2: A controlled drug release nanosystem via chemical stimulus was designed. 
Adapted from Lai et al., 2003.  
 
Up to this point, the characteristics and advantageous of MSNs and GNS have been 
discussed. For that matter, this study generated drug loaded MSNs with a thin layer of 
gold. The GNS in this study was also bio-functionalised; hence, the following section 
aptly describes integration of biospecificity features and selection of target scheme. 
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2.3 Target scheme - antibodies, peptide & aptamer (Apt) 
The ideal goal of nanodevices for cancer therapy is to design a high target specificity and 
affinity delivery system, and to attain an effective therapeutic drug concentration to the 
tumour. Besides, untoward toxicity to the surrounding tissues, of which usually occur 
when utilising conventional chemotherapy, can be minimised with targeted delivery 
system. Thus, the use of targeted-nanodevices may increase the effectiveness of 
nanoparticle homing. Generally, there are two major targeting schemes: passive and active 
targeting mechanisms (Chakraborty et al., 2011). Passive targeting refers to the 
accumulation of nanodevice at cancer tissues based on the body’s natural biological 
response toward pharmacological physiological or physicochemical factors of the devices 
(Shahbazi et al., 2012). This passive targeting, however, lacks selectivity in the 
mechanism of action. Alternatively, active targeting nanodevices can efficiently bind to 
target sites over the surrounding tissues thus, avoiding undesirable toxicity issues (Choi 
et al., 2010). This approach facilitates specific interaction between target moieties 
(antibodies, peptides, aptamer (Apt), sugar and small molecules) with either receptors or 
antigens that are overexpressed on cancer cell surface (Kumari et al., 2015, Fenart et al., 
1999). Of these moieties, monoclonal antibodies with high affinity and specificity have 
been the gold standard in targeted cancer therapy (Zito et al., 2016). Nonetheless, 
numerous problems when using antibodies-based therapy include large size of the 
antibody, high production cost and undesired immunogenicity that limit their use in 
medical field (Chames et al., 2009). As a consequence, relatively new target binding 
technology called aptamer has becoming a valuable alternative in targeted cancer therapy. 
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2.3.1 Aptamer (Apt) 
Nowadays, aptamer (Apt) have been a major focus of interest for bio-imaging, gene 
therapy and drug delivery applications. This owes to Apt’s inherent similarities but with 
more advantages over traditional antibodies like high affinity and specificity to target 
receptors or antigens, but at a fraction of the size. In 1990, Apt was first discovered by 
Ellington & Szostak and Tuerk & Gold as RNA ligands that were designed to selectively 
bind to T4 DNA polymerase and organic dyes, respectively (Tuerk and Gold, 1990, 
Ellington and Szostak, 1990). Apt is made up of either single-stranded RNA or DNA and 
is folded into three-dimensional conformations (Figure 2.3).  
 
 
Figure 2.3: Schematic diagram of Apt folded into three-dimensional conformations. 
Adapted from Sun et al, 2014.  
 
They are more economical and easier to prepare as the recipes do not involve cell culturing 
and animals uses. Furthermore, unlike antibodies, which undergo denaturation easily at 
higher temperature, Apt is thermodynamically stable, making it suitable to use at varying 
temperature for in vitro and in vivo studies. Moreover, Apt which usually are 20 - 60 
nucleotides long, are 20 - 25 times smaller than monoclonal antibodies. At such size, Apt 
may perform better and penetrates tumour deeper thus becoming ideal therapeutic agent 
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against cancers (Xiang et al., 2015, Zhu et al., 2012). Additionally, it is nearly impossible 
to design antibodies with no immunogenicity as they are often derived from animals like 
mouse, rabbit, donkey or even with humanised antibodies. In contrast, Apt is synthetic 
oligonucleotides that are not recognised as foreign bodies by immune system, and 
therefore immune response is avoided.                  
 
In 2004, the first Apt-targeted drug delivery system was reported by Farokhzad et al. 
(Farokhzad et al., 2004). The drug-loaded nanoparticles (NPs) incorporated with A10 
prostate-specific membrane antigen (PSMA) Apt for targeting PSMA protein 
overexpressed on prostate cancer epithelial cells. After 16 hours incubation of A10 PSMA 
Apt conjugated NPs in both prostate LNCaP and PC3 cell lines, the binding of the NPs 
was clearly noticeable in LNCaP cell line but not in PC3 cell line as PC3 cell line does 
not express PSMA protein. For another example, an MUC1 Apt-doxorubicin (DOX) 
complex was designed by Hu and colleagues in 2012 for selectively delivering 
chemotherapy drugs to liver (HepG2) and lung (A549) cancer cells  (Hu et al., 2012). The 
reduction of cell viability to nearly 70 % and 80 % for HepG2 and A549 cancer cells 
respectively was witnessed in this particular study. Also, this study demonstrated that the 
MUC1 Apt alone was not cytotoxic towards either cell lines.  
 
Among Apt, AS1411 Apt is the first to enter clinical trial (Bates et al., 2009). AS1411 
Apt, contains 26 bases with guanine rich sequence targeting nucleolin proteins, which is 
predominantly found on plasma membrane of most cancer cells. AS1411 Apt exerts anti-
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proliferative effect and does so by inhibiting the binding of nucleolin to bcl-2 mRNA 
(Aravind et al., 2012, Bates et al., 2009). Therefore, a number of nanocarrier systems 
conjugated with AS1411 Apt were designed as they promote cellular internalisation by 
interacting with nucleolin protein. This inhibition process matters because stabilisation of 
bcl-2 mRNA when bound to nucleolin stops cells from undergoing apoptosis, thus leading 
to the overproduction of cancer cells (Soundararajan et al., 2008, Otake et al., 2007, 
Derenzini et al., 1995). Interaction of AS1411 Apt with nucleolin at the plasma membrane 
and later endocytosed intracellularly would leave bcl-2 mRNA dangling, which eventually 
unlocking the apoptotic pathway (Fogal et al., 2009). 
 
2.4 Doxorubicin 
In the present study, combination of both chemo-photothermal therapy can be achieved 
with this synthesised gold nanoshell with mesoporous silica core (GNS) by co-loading 
chemotherapeutic drugs, doxorubicin (DOX) into mesoporous channel. DOX which is 
also named as Adriamycin, has molecular formula C27H29NO11 and molecular weight of 
543.52 g/mol. Figure 2.4 shows its chemical structure; it consists of four-membered ring 





Figure 2.4: Chemical structure of Doxorubicin (DOX). Adapted from Cacycle, 2018.  
 
DOX is isolated from actinobacteria called Streptomyces peucetius by mutating a 
daunomycin-producing strain and the produced DOX is then classified as a member of 
anthracycline family. Its chemotherapeutic potential for cancer treatment was first 
reported by Arcamone et al. in 1969 (Arcamone et al., 2000). In the meantime, Di Marco 
and co-workers proved DOX to have better therapeutic index when compared to 
daunorubicin, which is the precursor of DOX (DiMarco et al., 1969). In early 1970s, anti-
tumour efficiency of DOX had been evaluated in clinical trials and DOX was recognised 
as one of the most effective chemotherapeutic drugs (O'Bryan et al., 1973, Tan et al., 1973, 
Middleman et al., 1971). Within a few years DOX was approved by United States FDA 
for medical use. To date, DOX is still considered a mainstay chemotherapeutic drug due 
to its excellent anti-tumour efficacy against various type of cancers including Hodgkin’s 
lymphoma, breast-, ovarian-, lung-, liver- and thyroid cancer among others. Several 
mechanisms have been proposed for DOX-mediated anti-tumour effects: (1) intercalation 
between adjacent GC base pairs in DNA double helix, (2) inhibition of topoisomerase II 
activity and (3) induction of reactive oxygen species (ROS) production. These 
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mechanisms elicit DNA damage, leading to the activation of downstream targets that 
regulates apoptosis or cell cycle arrest.  
 
Despite DOX broad and promising applications in chemotherapy, the clinical use of 
doxorubicin is limited by indiscriminative toxic side effects as DOX is distributed into 
tissues and intracellular compartments via systemic circulation. Administration of DOX 
at cumulative doses ≥550 mg/m2 is associated with an increased incident of cardiac 
failure among cancer patients (Rahman et al., 2007). However, the exact molecular 
mechanism by which DOX inducing cardiomyopathy is still unclear. To overcome the 
indiscriminative toxic side effects associated with previous formulations, Doxil was 
developed and approved by United Stated FDA in 1995. Doxil, a formulation of 
doxorubicin encapsulated in liposomes was the first nanodrug used to treat several cancers 
including ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma 
(Barenholz, 2012). This new formulation had a successful increased of the survival rate 
and at the same time, reduced toxicity to the surrounding tissues. Nonetheless, 
administration of this nanodrug did not show a pronounced clinical efficacy in cancer 
treatment (Seynhaeve et al., 2013). Furthermore, the surface of this nanodrug was not 
functionalised with any targeting ligand and thus, provide the possibility of delivering the 
DOX to the healthy cells (Gao and Jiang, 2017). In short, nanodrugs with specific target 
and controlled release properties are essential to improve the clinical efficacy while   
sparing normal healthy cells. 
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2.5 Principle of two-photon excitation (TPE) 
The foundation of two-photon excitation (TPE) ideation was first proposed by Maria 
Goppert-Mayer in 1931 (Göppert-Mayer, 1931) however, this photophysical properties 
had not been practically tested until 1960s when laser with high photon intensities was 
invented (Kaiser and Garrett, 1961). Prior to further explanation about TPE, the 
knowledge on conventional single photon excitation needs to be understood. Single 
photon excitation is a linear process as it involves the direct transition of electron from 
fluorophore between ground and excited state by single photon in the Ultraviolet 
illumination. In contrast, TPE fluorescence accomplished the transition of electron from 
fluorophore between two electronic states by the almost simultaneous absorption of two 
photons (Oheim et al., 2006). Two photon absorption is considered as a nonlinear process 
where the first photon promoted an electron to virtual state and eventually brought to the 
excited state by the second photon (So et al., 2000). These can be explained using quantum 
theory, the energy of a photon is inversely proportional to its wavelength, thus, two photon 
should have a wavelength increased by a factor of two, to attain equivalent transition state 
excited with single photon (Benninger and Piston, 2014). As a result, fluorophore can be 
excited with long wavelength (infrared region) too other than short wavelength (ultraviolet) 




Figure 2.5: Jablonski (energy level) diagram of (a) single photon excitation and (b) two 
photon excitation. Adapted from So, 2002.  
 
In the present study, two-photon laser was employed to induce localised photothermal 
therapy (PTT) and simultaneously deforms the gold nanoshell (GNS) for the controlled 
release of DOX. Two photon laser is highly recommended in biological experiments as 
low average excitation power is needed and therefore, the degree of photodamage on 
biological specimen can be reduced (Hopt and Neher, 2001). Moreover, TPE exerts a 
deeper tissue penetration making it as a superior alternative to single photon laser. 
Additionally, the nonlinearity photon absorption of TPE permits the activation of GNS 
restricted to the focal point of the laser beam (Shen et al., 2016). This offers precise spatial 
control of GNS activation during cancer treatment, eventually minimising the off-target 
drift damage to the surrounding normal healthy tissues.  
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2.5.1 Photothermal therapy (PTT) 
One of the key elements in regulating the fate of biological systems ranging from single 
cell to tissues and organisms is temperature. Elevation of temperature above normal body 
temperature could lead to irreversible cell damage, and even vital organ dysfunction. On 
the brighter side, increase of temperature above normal (hyperthermia) in a control 
manner could be applied to get rid of undesired cancer cells. Thus, extensive efforts have 
been devoted to the development of novel nanoplatforms for controlled and localised 
hyperthermia in target area, while leaving nearby healthy tissues unharmed (Tsai et al., 
2018, Pattani and Tunnell, 2012, Gutwein et al., 2012). A promising technique to achieve 
controlled and localised hyperthermia is laser-induced photothermal therapy (PTT) 
(Mendes et al., 2017). Among all nanoparticles, gold nanoparticles (AuNP) are the most 
studied PTT materials due to excellent heat generation via non-radiative processes 
(Abadeer and Murphy, 2016). Non-equilibrium heat is established when electron of AuNP 
was photoexcited at incident photon. The relaxation of excited electron via electron-
electron scattering leading to the rapid temperature increment at the AuNP surface. The 
heat energy from electron is transferred to photon as a consequence of electron-photon 
collision and thermal equilibrium is reached (Link and El-Sayed, 2000). Lastly, AuNP is 
cooled down by dissipating the heat to surrounding medium via photon-photon interaction. 
The overall process of light induced thermal effect is summarised in Figure 2.6. 
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Figure 2.6: The overall process of photo-thermal conversion upon laser irradiation. 
Adapted from Webb and Bardhan, 2014.  
 
Gold nanoshells (GNS) are especially attractive for PTT because of their tunable plasmon 
resonance fall into the near infrared (NIR) region, where most of the biological tissues are 
relatively transparent to light in NIR region. The GNS mediated PTT in breast cancer cells 
was first performed by Hirsch et al. in 2003 (Hirsch et al., 2003). The loss of Calcein AM 
fluorescence in GNS treated group indicates cell damage after NIR laser irradiation. This 
phenomenon was not observed in control group with laser irradiation alone. The same 
group carried out a study in 2005 demonstrating dual imaging and NIR thermal therapy 
approach with GNS (Loo et al., 2005). This time, GNS was conjugated to either non-
specific antibodies or anti-HER2 antibodies and subsequently incubated in HER2-positive 
SKBr3 breast cancer cells. SKBr3 breast cancer cells incubated with anti HER2-
conjugated GNS underwent apoptosis within laser spot after NIR (820 nm) irradiation 
treatment for 7 minutes with output of 0.008 W/m2.  
 
In the following year, two cell types, SKBr3 breast cancer cells and HDF human dermal 
fibroblast (HER2 negative) were seeded side by side followed by incubation with HER2-
